Karachi: Liven Pharma Limited has released its financial statements for the fiscal year ending June 30, 2025, revealing a substantial financial downturn. The company reported a loss after taxation amounting to 584.46 million rupees, a stark contrast to the profit of 41.74 million rupees recorded in 2024. This financial decline was primarily influenced by increased expenses and reduced revenue.
The company's total assets decreased to 822.90 million rupees from 927.23 million rupees in the previous year. Share capital and reserves also saw a reduction, dropping to 633.86 million rupees from 749.69 million rupees in 2024. Non-current liabilities increased significantly to 98.62 million rupees, compared to 1.06 million rupees in the previous fiscal year, while current liabilities were reduced to 90.43 million rupees from 170.48 million rupees in 2024.
Revenue for 2025 stood at 127.27 million rupees, down from 245.09 million rupees in the prior year. This decline in revenue was accompanied by a rise in cost of sales, which reached 109.31 million rupees from 182.70 million rupees in 2024. The company also experienced a significant increase in administrative and general expenses, which jumped to 373.56 million rupees from 14.97 million rupees in the previous year. Selling and distribution expenses rose to 17.61 million rupees from 4.43 million rupees in 2024.
According to information available from the Pakistan Stock Exchange (PSX), Liven Pharma Limited's financial performance for the year ending June 30, 2025, reflects a challenging period marked by increased expenditures and declining revenues. The finance cost for the year was recorded at 785,675 rupees, up from 24,136 rupees in the previous fiscal year, and the company's total comprehensive loss for the year matched the loss after taxation at 584.46 million rupees.
Cash flows from operating activities also displayed a negative trend, with a net cash usage of 1.72 million rupees, contrasting with a cash generation of 13.80 million rupees in 2024. Cash flows from investing activities showed a net cash outflow of 32.84 million rupees, with significant investments made in property, plant, and equipment, and intangible assets. Financing activities provided a net cash inflow of 17.46 million rupees, aided by proceeds from loans and running finance.
The financial data for Liven Pharma Limited highlights the company's need to address the substantial financial challenges it faced during the fiscal year 2025, as evidenced by the significant movements in various financial metrics and the overall loss recorded.